Dr. David E. Cohen is the Vincent Astor Distinguished Professor of Medicine at Weill Cornell Medical College, and Chief of the Division of Gastroenterology and Hepatology in the Joan & Sanford I. Weill Department of Medicine.
Dr. Cohen received his M.D. from Harvard Medical School and his Ph.D. from the Graduate School of Arts and Sciences at Harvard University. He completed internal medicine residency training, as well as clinical and research fellowships in gastroenterology and hepatology, at Brigham and Women's Hospital, Harvard Medical School. Dr. Cohen served as Director of Hepatology at Brigham and Women's Hospital and Director of the Harvard-MIT Division of Health Sciences and Technology. He was a Professor and the Robert H. Ebert Endowed Chair at Harvard Medical School and a Professor in the Division of Health Sciences at Harvard-Massachusetts Institute of Technology from 2011-2016. He was a faculty member of Harvard Medical School's graduate program in biological and biomedical sciences from 2005-2016. Previously, Dr. Cohen served as an Associate Professor of Medicine and of Biochemistry in the Marion Bessin Liver Research Center at the Albert Einstein College of Medicine.
A member of the American Society for Clinical Investigation (ASCI) and the Interurban Clinical Club, Dr. Cohen is an internationally renowned physician-scientist with a major interest in the molecular regulation of hepatic lipid and glucose metabolism. Dr. Cohen is currently the editor of Hepatology, the premier journal in the field.
Allan Gibofsky, MD, JD
Scientific Advisory Board
Dr. Gibofsky is Professor of Medicine and Public Health at Weill Medical College of Cornell University, and Professor of Law at Fordham University. He is an Attending Physician and Rheumatologist at both New York Presbyterian Hospital and Hospital for Special Surgery, where he is co-Director of the Clinic for Inflammatory Arthritis.
Dr. Gibofsky received his undergraduate degree from Brooklyn College of the City University of New York, his MD from Weill Medical College of Cornell University and his law degree from Fordham University. He did his internship in Pathology, followed by a residency in Medicine at New York Hospital. He completed a fellowship in Rheumatology/Immunology jointly at Hospital for Special Surgery under Dr. Charles L. Christian, and at The Rockefeller University, where he worked in the laboratory of Dr. Henry G. Kunkel. Dr. Gibofsky has authored or co-authored numerous papers and text chapters, primarily on the immunogenetics of rheumatic diseases and legal aspects of medical practice. He is known for his work on mechanisms of host-microbe interactions in rheumatology, and, in particular for his basic and clinical studies on rheumatic fever.
Currently Secretary-Treasurer of The New York Rheumatism Association, Dr. Gibofsky is past-Chair of the Medical & Scientific Committee of the New York Chapter of The Arthritis Foundation and received their Physicians’ Leadership Award. He also served as a member of the local and national Arthritis Foundation Board of Trustees, and was Chair for Professional Education. Dr. Gibofsky has participated in numerous professional and public education programs, nationally and internationally. Dr. Gibofsky has held numerous leadership and officer positions in the American College of Rheumatology, and served as its President. Dr. Gibofsky is a Managing Director of The Rheumatology Education Group (TREG) LLC, a consortium of experts in the fields of rheumatology, musculoskeletal medicine and pain management.
Dr. Gibofsky’s civic activities include membership on the Brooklyn College Foundation Board of Trustees. He is a Jonas Salk Scholar of the City University and an Alumnus of the Year by Brooklyn College. He is a past president of the American College of Legal Medicine, past Chair of the American Board of Legal Medicine, and past-Chair of the Arthritis Advisory Committee to the Food and Drug Administration.
Rohit Loomba, MD, MHS
Scientific Advisory Board
Dr. Rohit Loomba is a tenured Professor of Medicine in the Division of Gastroenterology at the University of California, San Diego, and Adjunct Professor in the Division of Epidemiology. A leading expert in nonalcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH), Dr. Loomba is founding director of the UCSD NAFLD Research Center, as well as founder and principal investigator of the San Diego Integrated NAFLD Research Consortium (SINC).
Dr. Loomba and his collaborators lead research programs into applications of non-invasive biomarkers, especially imaging for assessment of fat, inflammation, cell injury, and fibrosis in patients with chronic liver diseases. The team conducts cutting edge clinical trials with novel therapies for treatment of NASH and liver fibrosis. This research incorporates genetics, epidemiology, and clinical trial design, imaging end-points, and integrated "OMICs" of the microbiome, metabolome and lipidome. After internal medicine training as Chief Resident at St. Luke's Hospital in St. Louis, Dr. Loomba completed an advanced fellowship in hepatology at the NIH/NIDDK, and a Master of Health Science degree from the combined NIH-Duke University Program, followed by a fellowship in gastroenterology at UCSD. He is board-certified in Gastroenterology and is now the Director of Hepatology at UCSD. His research is funded by the NIH, the NSF, and the American Gastroenterology Association. He is Principal Investigator for the adult hepatology site for the NIDDK-sponsored NASH Clinical Research Network (2009-19) at UCSD.
Dr. Loomba is an elected board member of the American Liver Foundation and co-chairs its Research Award Panel. He is also a member of the American Association for the Study of Liver Diseases (AASLD) and was elected Vice-Chair of the NAFLD Special Interest Group. Dr. Loomba serves as a Deputy editor of Hepatology, the premier journal in the field.
Robert A. Terkeltaub, MD
Scientific Advisory Board
Robert A. Terkeltaub, MD is a leading physician-scientist in the fields of arthritis and gout and other crystal diseases. Dr. Terkeltaub received his medical degree at McGill University in Montreal and completed his residency and speciality training in Internal Medicine and Clinical Rheumatology at Montreal General Hospital. He is Board-certified in Internal Medicine and Rheumatology. He is currently Professor of Medicine in the Rheumatology/Allergy/Immunology Division at the University of California San Diego (UCSD). Prior to his appointment at UCSD in 1985, he was associated with the Department of Immunology at the Scripps Research Institute.
Dr. Terkeltaub’s research focuses principally on gout, calcification, and osteoarthritis, and interfaces between metabolism and inflammation. An overview of his research can be viewed athttp://nizetlab.ucsd.edu/iii/investigators/terkeltaub.html. He has been the principal investigator on multiple clinical trials related to gout, including late-stage studies that have led to marketing approvals by the Food and Drug Administration (FDA). His research has been funded for more than 30 years by continuous peer-reviewed grants, and he has been the recipient of numerous professional and teaching awards. Dr. Terkeltaub regularly serves on Study Sections for the National Institutes of Health (NIH) and the Arthritis Research Foundation.
He is currently Co-Editor of the journal, Arthritis and Rheumatology. He has published more than 130 original peer-reviewed papers and authored more than 90 editorials, reviews, and book chapters. He is Editor of the 2 textbooks on gout and was the senior and corresponding author of the 2012 gout management guidelines manuscripts for the American College of Rheumatology. Dr. Terkeltaub is inaugural President of G-CAN, the global Gout, hyperuricemia and Crystal Arthropathy research collaborative Network.